Skip to main content
    E

    Evogene (EVGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.39
    +0.02 (+5.58%)

    Market Cap: $6.70M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Evogene (EVGN) Earnings: Report Dates and Results

    Updated Aug 18, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Evogene (EVGN) is confirmed to report earnings on Nov 19, 2026, before the open. In the quarter ended Jun 30, 2026, Evogene reported EPS of -$0.13, above the -$0.27 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    41%(15/37)
    Avg Surprise
    -19.85%
    Streak
    1 Q

    Upcoming Estimates

    Reports Nov 19, 2026 before openPeriod ending Sep 30, 2026
    EPS Consensus-$0.19
    Range-$0.19 - -$0.19
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.27+29.6%
    60d ago-$0.27+29.6%
    30d ago-$0.27+29.6%
    7d ago-$0.27+29.6%
    Current-$0.19
    Revenue Consensus
    $365.00K
    Range$365.00K - $365.00K
    1 analysts
    Reports Mar 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.20
    RangeN/A
    3 analysts
    Revenue Consensus
    $397.80K
    Range$382.20K - $409.50K
    3 analysts

    Next Report

    EVGN has a confirmed report date of Nov 19, 2026, before the open.

    EVGN Earnings Call

    The latest EVGN earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, EVGN beat 15, missed 21 and matched 2. Revenue for the quarter ended Jun 30, 2026 was $347000, down 60.7% from $884000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.13-$0.27-$0.27 - -$0.27+51.85%BeatN/A11 up, 0 downAug 18, 2026$347000
    Mar 31, 2026-$0.61-$0.27-$0.27 - -$0.27-125.93%MissN/A10 up, 0 downMay 20, 2026$334000
    Dec 31, 2025-$0.62-$0.41N/A-50.59%Miss-1129.0%11 up, 1 downMar 5, 2026$314000
    Sep 30, 2025-$0.46-$0.41-$0.41 - -$0.41-12.20%MissN/A12 up, 0 downNov 20, 2025$312000
    Jun 30, 2025-$0.50-$0.63-$0.65 - -$0.61+20.63%BeatN/A21 up, 1 downAug 28, 2025$884000
    Mar 31, 2025-$0.38-$0.50-$0.53 - -$0.48+24.00%BeatN/A21 up, 0 downMay 21, 2025$2.44M
    Dec 31, 2024$0.06-$0.73-$0.76 - -$0.69+108.28%BeatN/A21 up, 1 downMar 6, 2025$1.61M
    Sep 30, 2024-$1.31-$1.01-$1.17 - -$0.85-29.70%MissN/A21 up, 1 downNov 21, 2024$1.74M
    Jun 30, 2024-$1.06-$1.20-$1.30 - -$1.20+11.67%BeatN/A20 up, 0 downAug 22, 2024$605000
    Mar 31, 2024-$0.80-$0.90-$1.00 - -$0.80+11.11%BeatN/A21 up, 0 downMay 23, 2024$4.19M
    Dec 31, 2023-$1.30-$1.40-$1.40 - -$1.40+7.14%BeatN/A20 up, 0 downMar 7, 2024$578000
    Sep 30, 2023-$0.80-$1.57-$1.70 - -$1.40+49.04%BeatN/A30 up, 0 downNov 15, 2023$3.77M
    Jun 30, 2023-$1.70-$1.75-$1.90 - -$1.60+2.86%BeatN/A20 up, 0 downAug 17, 2023$654000
    Mar 31, 2023-$1.50-$1.60-$1.60 - -$1.60+6.25%BeatN/A10 up, 0 downMay 18, 2023$641000
    Dec 31, 2022-$0.07-$0.20-$0.21 - -$0.19+65.00%BeatN/A20 up, 0 downMar 9, 2023$641000
    Sep 30, 2022-$1.60-$1.97N/A+18.78%BeatN/A10 up, 0 downNov 17, 2022$466000
    Jun 30, 2022-$2.10-$1.90N/A-10.53%MissN/AN/AN/AAug 31, 2022$312000
    Mar 31, 2022-$2.00-$1.80N/A-11.11%MissN/AN/AN/AMay 26, 2022$237000
    Dec 31, 2021-$1.80-$2.00-$2.00 - -$1.50+10.00%BeatN/A20 up, 0 downMar 10, 2022$311000
    Sep 30, 2021-$1.90-$1.77-$1.90 - -$1.50-7.34%MissN/A20 up, 0 downNov 17, 2021$151000
    Jun 30, 2021-$1.50-$1.65N/A+9.09%BeatN/AN/AN/AAug 11, 2021$135000
    Mar 31, 2021-$1.70-$1.80N/A+5.56%BeatN/AN/AN/AMay 26, 2021$333000
    Dec 31, 2020-$2.50-$1.70N/A-47.06%MissN/AN/AN/AMar 3, 2021$351000
    Sep 30, 2020-$0.17-$0.17N/A0.00%In lineN/AN/AN/ANov 18, 2020$316000
    Jun 30, 2020-$0.16N/AN/AN/AN/AN/AN/AN/AAug 5, 2020$298000
    Mar 31, 2020-$0.24N/AN/AN/AN/AN/AN/AN/AMay 26, 2020$75000
    Dec 31, 2019-$0.24$0.34N/A-170.59%MissN/AN/AN/AMar 4, 2020$116000
    Sep 30, 2019-$0.16$0.18N/A-188.89%MissN/AN/AN/ANov 13, 2019$97000
    Jun 30, 2019-$0.16$0.19N/A-184.21%MissN/AN/AN/AJul 31, 2019$192000
    Mar 31, 2019-$0.15$0.30N/A-150.00%MissN/AN/AN/AMay 28, 2019$348000
    Dec 31, 2018-$0.23-$0.19N/A-21.05%MissN/AN/AN/AMar 13, 2019$635000
    Sep 30, 2018-$1.90-$1.80N/A-5.56%MissN/AN/AN/ANov 14, 2018$367000
    Jun 30, 2018-$1.90-$1.90N/A0.00%In lineN/AN/AN/AAug 8, 2018$379000
    Mar 31, 2018-$2.10-$1.90N/A-10.53%MissN/AN/AN/AMay 29, 2018$366000
    Dec 31, 2017-$2.40-$2.10-$2.10 - -$2.10-14.29%MissN/A1N/AFeb 28, 2018$734000
    Sep 30, 2017-$2.00-$1.70N/A-17.65%MissN/AN/AN/ANov 22, 2017$748000
    Jun 30, 2017-$1.80-$1.40N/A-28.57%MissN/AN/AN/AAug 10, 2017$1.18M
    Mar 31, 2017-$1.90-$1.80N/A-5.56%MissN/AN/AN/AMay 17, 2017$721000
    Dec 31, 2016-$2.60-$1.80N/A-44.44%MissN/AN/AN/AFeb 27, 2017$1.18M
    Sep 30, 2016-$2.00-$0.70N/A-185.71%MissN/AN/AN/ANov 21, 2016$1.54M
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.96, after -$3.11 the year before. It was -$7.70 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.96N/A
    Dec 31, 2024-$3.11N/A
    Dec 31, 2023-$5.30N/A
    Dec 31, 2022-$5.77N/A
    Dec 31, 2021-$6.90N/A
    Dec 31, 2020-$3.07N/A
    Dec 31, 2019-$0.71N/A
    Dec 31, 2018-$6.13N/A
    Dec 31, 2017-$8.10N/A
    Dec 31, 2016-$7.70N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 6,200 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20266,1995
    2026Q1Mar 31, 20264,4836
    2025Q4Dec 31, 20253,8763
    2025Q3Sep 30, 20255,9183
    2025Q2Jun 30, 20254,6103
    2025Q1Mar 31, 20255,8183
    2024Q4Dec 31, 20246,3664
    2024Q3Sep 30, 20245,5644

    2026Q2 Earnings Call

    Opening remarks

    Ofer Haviv CEO Thank you for joining Evogene's Second Quarter 2026 Analyst Call. Today's call will be somewhat different from our usual format. Joining me is Mr. Nir Nimrodi, Chairman of Evogene's Board of Directors. Nir will begin by presenting the Board's response to the recent demand by a group of dissident shareholders seeking to replace the company's Board. Following Nir's remarks, I will discuss the company's achievements during the first half of the year and our near-term expectations. We will conclude with a review by Mrs. Polina Ravzin, Evogene's VP Finance, of our financial results, followed by a Q&A session. Nir, please go ahead.

    Nir Nimrodi Chairman Thank you, Ofer. Good morning, everyone. As Chairman, my primary responsibility together with my fellow directors is to position Evogene for long-term sustainable value creation. We share the frustration with the historical share price, and we acted with urgency and determination to address it. Over the past 18 months, we haven't just talked about change, we have delivered it. We have fundamentally transformed Evogene into a lean, AI-driven leader in computational chemistry for pharmaceuticals and crop protection. We have streamlined operations, reduced costs and optimized our portfolio. The question today is not whether change is necessary — change has already been executed. The question is how we accelerate the momentum we have created. Interrupting this transformation precisely as it enters its most promising phase is a risk we cannot afford. Our strategy is already delivering tangible results. We established ChemPass as our core platform, building the first-in-class generative small molecule foundation model and integrating autonomous AI agents in partnership with Google Cloud. We secured six key drug development agreements with leading biotechnology companies and premier academic institutions, validating the commercial value of our AI-driven platform, ChemPass AI. We reduced headcount from 117 to 38, creating a highly focused, agile organization. We lowered cash burn from approximately $20.5 million in 2024 to an expected $8.5 million to $9.5 million in 2026 with further reductions anticipated in 2027. We raised approximately $11.1 million in new capital, securing the financial runway to execute our plans. And lastly, we monetized Lavie Bio, selling it to ICL for $15.25 million, licensed Biomica's Phase I asset to Lishan Biotech, focused Casterra on the Brazil SAF market and advanced AgPlenus novel fungicide discovery. Another strong indication of confidence in Evogene's long-term potential comes from Mr. Leon Recanati, a member of Evogene's Board of Directors and a highly respected investor. Mr. Recanati recently made a significant investment in Evogene and today he is one of the largest shareholders of the company. This recent investment reflects his strong belief in Evogene's strategy, technology and long-term value creation potential.

    Frequently Asked Questions About EVGN

    When is Evogene's next earnings date?

    Evogene's next earnings report is confirmed for Nov 19, 2026, before the open.

    Did EVGN beat earnings estimates last quarter?

    Yes. Evogene reported EPS of -$0.13 for the quarter ended Jun 30, 2026, above the -$0.27 estimate, a 51.85% surprise.

    What EPS do analysts expect from EVGN next quarter?

    The consensus EPS estimate for Evogene for the quarter ended Sep 30, 2026 is -$0.19 from 1 analyst, with estimates from -$0.19 to -$0.19.

    How often does EVGN beat earnings estimates?

    Evogene beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -1.71%.

    Does EVGN report before or after the market opens?

    Evogene is confirmed to report on Nov 19, 2026, before the market opens.